Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases. Its lead candidate, PALI-2108, targets inflammatory bowel disease (IBD), including ulcerative colitis and fibrostenotic Crohn’s disease, using a localized PDE4 inhibitor prodrug approach. The company focuses on precision medicine, strategic collaborations, and advancing drug candidates through clinical trials to address unmet medical needs.
This description was generated via AI from an annual report. Updated about 1 year ago.